Biosimilar Solutions’ registrational clinical trials for BSC1020 and BSC0826, both a recombinant granulocyte colony-stimulating factor (G-CSF) analogue filgrastim, is designed to determine the similarity between the biosimilars and their reference product, Amgen’s Neupogen (filgrastim) and Neulasta (Pegfilgrastim), respectively. The design of the clinical trials of BSC1020 was reviewed and approved by the US Food and Drug Administration (FDA) and is planned to be completed in the summer of 2022.

Filgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment.

There are over 12 biosimilar filgrastim and 17 biosimilar pegfilgrastim approved for use worldwide [1].

Also, Biosimilar Solutions has entered into a long-term collaboration manufacturing and operations agreement with OcyonBio and has plans to complete a technology transfer to begin manufacturing in Puerto Rico in mid-March 2022. The plant will be located in Aguadilla, Puerto Rico, and it will include more than 95,000 sq ft of cleanroom and biomanufacturing space, with biosimilar production scheduled in 2022.

OcyonBio provides autonomous manufacturing capacity with interconnected infrastructure and systems to support phased appropriate development for early development, pre-clinical, clinical and commercial start. Biosimilar Solutions expects to manufacture in-house commercial-scale facilities for recombinant proteins and monoclonal antibodies (mammalian, microbial cell culture, fill-finish for vials and syringes).

Robert Salcedo, CEO of OcyonBio said that with this partnership development manufacturing organization model OcyonBio will usher in these biosimilars to the US. Biosimilar Solutions will have efficient control over current good manufacturing practice (cGMP) production in a facility that has been designed to meet global regulatory expectations and readiness for the European Medicines Agency, FDA and global regulatory audits.

Related articles
US market trends in oncology/nephrology supportive care and inflammation biosimilars

Biosimilars approved in the US

Biosimilars of filgrastim

Biosimilars of pegfilgrastim

Reference
1. Kang HN, et al. Biosimilars – status in July 2020 in 16 countries. Generics and Biosimilars Initiative Journal (GaBI Journal). 2021;10(1):4-32. doi: 10.5639/gabij.2021.1001.002

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.